Glenmark Pharma launches osmotic laxative Polyethylene Glycol in the U.S.

Glenmark Pharmaceuticals have a presence in more than 80 countries, and the US market will see the introduction of Polyethylene Glycol 3350 Powder for Solution as an over-the-counter product. The above product is a generic version of Bayer HealthCare LLC MiraLAX Powder for Solution. Polyethylene glycol is an osmotic laxative. It treats and prevents occasional constipation. For the most recent 52-week period ending February 22, 2025, Nielsen syndicated data shows that the MiraLAX Powder for Solution OTC market generated yearly sales of roughly $555. 7 million.

In response to the increasing need for a new supplier in this category, we are pleased to announce the launch of Polyethylene Glycol 3350 Powder for Solution 17 grams/capful, stated Marc Kikuchi, president and business head of North America. Glenmark Pharmaceuticals will launch Polyethylene Glycol 3350 Power for Solution. Nielsen syndicated data shows that the MiraLAX Powder for Solution OTC market generated yearly sales of roughly $555. 7 million for the most recent 52-week period ending February 22, 2025.

Marc Kikuchi, president and business head of North America, said: "We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category."